Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
32 hedge funds and large institutions have $137M invested in Cyteir Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
380% more capital invested
Capital invested by funds: $28.5M → $137M (+$108M)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
7% more funds holding
Funds holding: 30 → 32 (+2)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$5.11M |
| 2 |
AC
Aldebaran Capital
Carmel,
Indiana
|
+$246K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$162K |
| 4 |
Morgan Stanley
New York
|
+$154K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.11M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.07M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$503K |
| 4 |
Millennium Management
New York
|
-$155K |
| 5 |
NM
Newtyn Management
New York
|
-$109K |
CYT Hedge Fund Activity: Q1 2023 in Review
32 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q1 2023, worth a combined $137M — up 380% from $28.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CYT positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was BML Capital Management, opening a new position worth an estimated $5.11M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.11M sold.
- 32 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q1 2023, up from 30 in Q4 2022.
- Funds reported $137M of Cyteir Therapeutics, Inc. Common Stock stock for Q1 2023, up 380% quarter-over-quarter.
- 7 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of +2 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q1 2023 was BML Capital Management, an estimated $5.11M added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q1 2023 was Baker Bros. Advisors, an estimated $4.11M sold.
Based on aggregated 13F filings for Q1 2023.